Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares

Mittie Doyle, Chief Medical Officer at Avalo Therapeutics, sold 1,000 shares of the company's common stock on August 17, 2026, for $20.00 per share, amounting to a total of $20,000. This sale was executed under a pre-arranged Rule 10b5-1 trading plan, adopted by Doyle on November 13, 2025. Simultaneously, Doyle purchased 1,000 shares of Avalo Therapeutics common stock as part of exercising stock options, paying $12.65 per share, totaling $12,650.

Doyle now directly holds 51,776 shares of the company's stock, in addition to owning 123,750 derivative securities in the form of stock options. The insider sale follows AVTX stock's impressive 108% return over the past year, currently trading at $19.74, despite analysts' concerns about its valuation relative to fair value. Avalo Therapeutics has also been added to the Russell 2000 and 3000 indexes.